Seegene, Inc. (096530.KQ)
- Previous Close
26,300.00 - Open
26,100.00 - Bid 26,550.00 x --
- Ask 26,600.00 x --
- Day's Range
25,600.00 - 26,650.00 - 52 Week Range
19,500.00 - 35,950.00 - Volume
309,723 - Avg. Volume
359,647 - Market Cap (intraday)
1.225T - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 9, 2025
- Forward Dividend & Yield 800.00 (3.04%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
39,500.00
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
www.seegene.comRecent News: 096530.KQ
View More
Performance Overview: 096530.KQ
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 096530.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 096530.KQ
View MoreValuation Measures
Market Cap
1.21T
Enterprise Value
834.36B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.93
Price/Book (mrq)
1.24
Enterprise Value/Revenue
2.01
Enterprise Value/EBITDA
12.35
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.91%
Return on Assets (ttm)
-0.84%
Return on Equity (ttm)
-2.02%
Revenue (ttm)
414.25B
Net Income Avi to Common (ttm)
-20.34B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
522.61B
Total Debt/Equity (mrq)
14.63%
Levered Free Cash Flow (ttm)
37.7B